OLIGOMA Trial: SBRT Extends PFS in Oligometastatic Breast Cancer
oncodaily - The OLIGOMA trial presented at ESTRO 2026 brings new attention to one of the most debated questions in metastatic breast cancer: can treating limited metastatic sites with stereotactic body radiotherapy […]
AI Summary: A randomized trial shows stereotactic body radiotherapy (SBRT) targeting limited metastatic breast lesions prolongs progression‑free survival, offering longer disease control for selected patients with oligometastatic disease. Toxicity was manageable, suggesting SBRT could become a pragmatic, tissue‑sparing option to delay systemic therapy escalation.
- ESTRO reaction: clinicians and advocates amplify SBRT findings (3)
- EXTEND and practice: metastasis-directed therapy, guidelines, and AI (4)
- OLIGOMA: SBRT extends PFS in oligometastatic breast cancer (3)
- All Other Stories
ESTRO reaction: clinicians and advocates amplify SBRT findings
EXTEND and practice: metastasis-directed therapy, guidelines, and AI
OLIGOMA: SBRT extends PFS in oligometastatic breast cancer
All Other Stories
Related Stories
Small study reports 100% one‑year survival after lung transplant / 20 hrs
High‑dose targeted radiation shows promise for huge bile duct tumors / 3 months
Short‑term fasting may boost chemotherapy response in ovarian cancer / 4 wks
Implanted tile radiotherapy reduces brain metastasis recurrence / 5 wks
Two high‑dose radiotherapy sessions safely treat localized prostate cancer / 7 wks
ESMO issues new metastatic colorectal cancer clinical guideline / 2 months
Ovarian suppression with tamoxifen cuts recurrence in premenopausal breast cancer / 5 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Long COVID, Infant Health, Biotech, Pancreatic Cancer and look for the RSS link.
StackHealth Time Machine